Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by EbbFlow88on Sep 12, 2023 12:28pm
188 Views
Post# 35631762

RE:RE:Interesting Stats

RE:RE:Interesting StatsAn example in 2022 annual report:

On the Income Statement, it reads "Amortization of Intangible Assets" = $51.7M

Under Operating Cash Flow, it reads "Depcreciation & Amortization" = $62.6M

So, the majority is intangible assets which I understand as our drug rights. Only 11M is for GBT/hard assets.

Goodwill is not amortized. 

If the drugs are accurately amortized, which I assume is unlikely as some of the drugs could far outlast their amortization, then that money will have to be reinvested in replacing those drugs. So, what % of that is a real cost to GUD? 90%, 80%? 60%? I have no idea

If you're being conservative and say 90% is a real cost, then that 51.7 turns to a cost of $46.5M which would turn OCF to a free cash flow of negative 6M for 2022. Eventually, it's the FCF that will really matter. In the short term, OCF is great. 


<< Previous
Bullboard Posts
Next >>